Multiple Sclerosis: Symptoms and Treatments

What is Multiple Sclerosis?

Multiple Sclerosis (MS) is recognized as a chronic and often progressive disease that affects the central nervous system (CNS) . The CNS, comprising the brain, spinal cord, and optic nerves, is the body's command center, controlling everything from movement to thought . In MS, the body's own immune system mistakenly launches an attack on the myelin sheath, a crucial protective layer that surrounds the nerve fibers, or axons, in the CNS . This myelin is essential for the efficient and rapid transmission of nerve signals, akin to the insulation around an electrical wire .

When the myelin is damaged, a process known as demyelination, the underlying nerve fibers become exposed. This exposure can disrupt the normal flow of electrical impulses, causing them to slow down, become distorted, or even be completely blocked between the brain and other parts of the body . In some instances, the nerve fibers themselves can also sustain damage . While the body has a capacity to repair this myelin damage, the process is often imperfect. This imperfect repair leads to the formation of hardened scar tissue or lesions, also called sclerosis or plaques, at multiple sites throughout the CNS . The term "multiple sclerosis" directly reflects this characteristic widespread scarring .

The impact of MS varies considerably from person to person, largely depending on the specific areas of the CNS where these lesions occur and the extent of the damage . Because different regions of the brain and spinal cord control different bodily functions, the symptoms of MS can be diverse, affecting aspects such as vision, sensation, coordination, and movement . The course of the disease is also highly unpredictable; individuals may experience periods of intense symptoms (relapses or exacerbations) followed by periods of improvement (remissions), while others may have a more gradual progression of symptoms . Some individuals might have mild, infrequent symptoms, whereas others may face significant and increasing disability .

The way that myelin's damage affects nerve signal transmission can be intuitively understood by comparing it to the insulation on an electrical wire . Just as damaged insulation can cause a short circuit or a weak electrical flow, damage to the myelin sheath disrupts the efficient conduction of nerve impulses. This disruption can lead to a variety of neurological symptoms depending on which nerve pathways are affected.

A key characteristic of MS is its highly variable nature . The disease manifests differently in each individual, with variations in the types of symptoms experienced, their severity, and the pattern of disease progression. This variability arises because MS lesions can occur in virtually any part of the central nervous system, and the specific location and size of these lesions differ significantly not only between different people but also within the same person over time. Consequently, it is essential to recognize that each person's journey with MS is unique, and experiences should not be broadly generalized.

Different Types of MS

Relapsing-Remitting MS (RRMS):

RRMS is the most frequently diagnosed form of MS, accounting for approximately 80-85% of cases at the time of initial diagnosis . This type of MS is defined by clearly distinct episodes of neurological symptoms, known as relapses, flare-ups, or exacerbations . These relapses represent periods of active disease where new symptoms may appear or existing symptoms may worsen. The duration of these attacks can vary, lasting from a few days to several weeks or even months .

Following a relapse, individuals with RRMS experience periods of remission . During these remission phases, there is a partial or complete recovery from the symptoms experienced during the relapse. Symptoms may lessen significantly or even disappear entirely, and the individual may return to a level of functioning similar to what it was before the attack. These remission periods can last for varying lengths of time, from months to years . Importantly, during remissions, the disease itself does not appear to progress . However, it's possible that after each relapse, the recovery may not be complete, and some symptoms might persist, potentially becoming permanent over time . This can lead to a gradual accumulation of disability, especially if the disease is not managed effectively . RRMS can be further characterized based on its activity and progression. It can be active, meaning there are relapses and/or evidence of new lesions on MRI scans, or not active. It can also be worsening, indicating a confirmed increase in disability following a relapse, or not worsening . Understanding these nuances is important for making informed treatment decisions and tailoring management strategies to the individual's specific disease course.

The fact that disability in RRMS might not worsen between relapses but can accumulate following each relapse underscores the importance of proactive management. While the remissions offer respite from active symptoms, the potential for residual effects from each attack highlights the progressive nature of the disease, even in its relapsing form. This understanding emphasizes the need for individuals with RRMS to engage in disease-modifying therapies early in their diagnosis to potentially reduce the frequency and severity of relapses and minimize the long-term accumulation of disability.

Primary Progressive MS (PPMS):

Primary Progressive MS affects approximately 10-15% of people diagnosed with MS . In contrast to RRMS, PPMS is marked by a gradual and continuous worsening of neurological function and accumulation of disability from the onset of the disease . Individuals with PPMS do not experience the distinct relapses and remissions that are characteristic of RRMS, although there might be periods where the progression of symptoms temporarily plateaus or there are minor improvements . The rate of progression in PPMS can vary among individuals, but it is generally a steady decline in function over time . PPMS tends to be diagnosed at a slightly older age compared to RRMS, often in people in their 40s , and it affects men and women in roughly equal numbers, unlike the higher prevalence in women seen with RRMS . Early symptoms of PPMS can be subtle and may include a gradual development of walking difficulties that worsen progressively .

The lack of distinct relapses in PPMS suggests that the underlying disease mechanisms might differ from those in RRMS. While RRMS is characterized by acute inflammatory attacks, PPMS may involve a more chronic and insidious process of neurodegeneration from the beginning. This difference in pathology has significant implications for treatment, as many disease-modifying therapies approved for MS primarily target the inflammatory aspects of the disease that are prominent in RRMS. Research into PPMS is actively exploring therapies that can target the progressive neurodegenerative component.

Secondary Progressive MS (SPMS): For a significant number of individuals who initially have RRMS, the disease will eventually transition into a phase known as Secondary Progressive MS . SPMS is characterized by a more continuous pattern of disability progression . The distinct relapses and periods of remission that were typical of RRMS become less frequent, and instead, there is a steady worsening of neurological function and an increase in the level of disability over time . While some individuals with SPMS may still experience occasional relapses, often referred to as active SPMS, the hallmark of this stage is the ongoing progression of symptoms that occurs independently of these relapses . Others may enter a phase where relapses cease altogether, but the disability continues to worsen; this is sometimes referred to as non-active SPMS . The transition from RRMS to SPMS typically occurs after a considerable period, often 10 to 20 years, of living with RRMS . However, the use of disease-modifying therapies during the RRMS phase has shown potential in delaying or even preventing this transition in some individuals .

The shift from RRMS to SPMS often indicates a change in the dominant pathological processes of the disease. While the early stages of MS are often characterized by inflammation driving relapses, SPMS typically involves a greater contribution from neurodegeneration, the progressive loss of nerve cells. This evolution in the disease course necessitates a shift in treatment focus, with an emphasis on therapies that can address this underlying neurodegenerative component in addition to managing any ongoing inflammatory activity. Recognizing this transition is crucial for both individuals with MS and their healthcare providers to adapt management strategies and explore appropriate treatment options for this more progressive phase of the disease.

Clinically Isolated Syndrome (CIS):

Clinically Isolated Syndrome (CIS) refers to a first episode of neurological symptoms that are caused by inflammation and demyelination in the central nervous system and last for at least 24 hours . These symptoms are similar to those experienced by people with MS, such as vision problems, weakness, numbness, or balance issues . However, having a CIS episode does not definitively mean that the individual will go on to develop multiple sclerosis . In some cases, it may be an isolated event, and the person may never experience further neurological symptoms. The likelihood of developing MS after a CIS episode is increased if an MRI scan of the brain reveals lesions that are characteristic of MS . Studies have shown that initiating treatment with disease-modifying therapies in individuals who have experienced CIS and are considered to be at high risk for developing MS can delay the onset of a definite MS diagnosis .

CIS represents a significant early stage in the potential development of MS . The identification of MRI lesions consistent with demyelination at the time of a first neurological event is a strong indicator of an increased risk for future MS. Therefore, it is crucial for individuals experiencing symptoms suggestive of CIS to undergo a thorough neurological evaluation, including an MRI scan, to assess their risk of progressing to MS and to discuss potential early treatment options with their healthcare provider. Early intervention at this stage may help to modify the long-term course of the disease.

Radiologically Isolated Syndrome (RIS):

Radiologically Isolated Syndrome (RIS) is characterized by the incidental finding of white matter lesions on an MRI of the brain or spinal cord that are suggestive of demyelination (similar to those seen in MS), in individuals who have no history of clinical symptoms consistent with MS . These MRI abnormalities are often discovered when a scan is performed for an unrelated reason, such as to investigate headaches or after a minor head trauma . While individuals with RIS do not have any symptoms of MS, research has shown that a notable proportion of them will eventually go on to develop clinical symptoms (CIS) and subsequently be diagnosed with MS. Studies indicate that over half of individuals with RIS may develop MS within ten years of the initial MRI finding . Certain factors have been identified that may increase the risk of progression from RIS to clinical MS. These include younger age at the time of RIS diagnosis, the presence of lesions in the spinal cord, and the detection of oligoclonal bands in the cerebrospinal fluid, which is obtained through a lumbar puncture . Currently, there are no established guidelines for treating RIS, and the decision of whether or not to initiate disease-modifying therapy in individuals with RIS is complex. It involves carefully considering the potential benefits of early intervention against the risks associated with long-term treatment, based on an individual's likelihood of developing clinical MS.

The identification of RIS highlights the possibility of preclinical disease activity in MS. The presence of MRI lesions characteristic of demyelination in the absence of any neurological symptoms suggests that the pathological processes of MS may begin silently, potentially years before any clinical manifestations. This finding has spurred research into the very early stages of MS and the potential for interventions even before symptoms appear. Understanding the factors that predict which individuals with RIS will progress to clinical MS is a key focus of ongoing research, as this knowledge could help inform decisions about early treatment and monitoring strategies.

Common Symptoms of MS

Fatigue:

Fatigue is one of the most frequently reported and often most debilitating symptoms experienced by individuals with MS, affecting as many as 95% of people with the condition . Unlike the typical tiredness experienced after physical exertion, MS fatigue is often described as an overwhelming and persistent sense of exhaustion that is not relieved by rest . Individuals may report feeling drained even after adequate sleep, and the fatigue can fluctuate in severity throughout the day .

The nature of MS fatigue can be both physical and mental . Physically, individuals may experience a heavy feeling in their limbs and a lack of energy to perform even simple tasks . Mentally, they might struggle with concentration, memory, and overall cognitive function . MS fatigue can be categorized as primary or secondary . Primary fatigue is believed to be a direct consequence of the neurological damage caused by MS, such as the disruption of nerve pathways due to demyelination . Secondary fatigue, on the other hand, can result from other MS-related issues, including pain, sleep disturbances, depression, or the side effects of certain medications . Factors such as heat and humidity are also known to worsen fatigue in many individuals with MS .

The complex nature of fatigue in MS necessitates a multifaceted approach to management. This often involves a combination of pharmacological interventions, such as medications like amantadine or modafinil, and non-pharmacological strategies. Addressing underlying conditions that can contribute to secondary fatigue, such as sleep disorders or depression, is crucial. Additionally, lifestyle adjustments, including pacing activities, prioritizing tasks, and incorporating rest periods throughout the day, can significantly help individuals manage their energy levels and cope with this challenging symptom.

Difficulty Walking and Mobility Issues:

Difficulties with walking and overall mobility are frequently encountered by individuals with MS, often stemming from a combination of neurological impairments . Muscle weakness, particularly in the legs, is a common contributor, making it difficult to lift the legs properly and leading to a dragging of the toes, known as foot drop . Muscle stiffness and tightness, or spasticity, can also significantly impede movement and coordination . Problems with balance and coordination, termed ataxia, can result in an unsteady gait and an increased risk of falls . Sensory deficits, such as numbness or tingling in the feet, can further complicate walking by affecting an individual's awareness of their foot placement .

These challenges can manifest in various ways, including unsteadiness while walking or turning, a noticeable slowing of walking speed, shorter steps, a reduced sense of confidence in walking, and a need for support from walls, furniture, or other people . Some individuals may experience a heavy sensation in their legs when attempting to step forward or weakness in the legs when bearing weight . Foot drop can cause the front of the foot to not lift correctly, leading to tripping or stumbling . Balance issues can result in a swaying, uncoordinated gait, sometimes referred to as a "drunk walk," and can make navigating uneven surfaces or stairs particularly difficult .

The interplay between balance and walking difficulties in MS highlights the need for a comprehensive rehabilitation strategy. Damage to the cerebellum, the part of the brain responsible for balance, can directly lead to instability, which in turn impacts the ability to walk steadily. Similarly, muscle weakness in the legs, often caused by lesions in the spinal cord, can affect balance when standing or walking. Therefore, effective management of these issues often involves a combination of approaches. Physical therapy plays a crucial role in improving posture, gait, and muscle strength . Assistive devices, such as canes, walkers, or orthotics like ankle-foot orthoses (AFOs), can provide support and improve walking efficiency . In some cases, medications may be prescribed to help manage spasticity or improve walking speed . Addressing sensory issues and implementing fall prevention strategies are also essential components of managing mobility challenges in MS .

Vision Problems:

Visual disturbances are frequently experienced by individuals with MS and can sometimes be the first symptom that leads to diagnosis . The three most common vision problems associated with MS are optic neuritis, double vision (diplopia), and involuntary eye movements (nystagmus) .

Optic neuritis involves inflammation of the optic nerve, which transmits visual information from the eye to the brain . This inflammation can lead to a variety of symptoms, including blurry vision, a decrease in vision in one eye, pain when moving the eye, and a change in the way colors are perceived (often appearing faded or washed out) . Double vision, or diplopia, occurs when the muscles that control eye movement are weakened or uncoordinated due to nerve damage, resulting in the perception of seeing two images of a single object . Nystagmus is characterized by involuntary, rapid, and uncontrolled movements of the eyes, which can be side-to-side, up-and-down, or rotary. This can sometimes lead to a sensation that the world is moving (oscillopsia), as well as dizziness and balance problems .

While vision problems associated with MS can be concerning, it's important to note that in many cases, eyesight can return to normal, either on its own or with treatment . Optic neuritis, for example, is often transient, and vision typically recovers within a few weeks to months . Depending on the severity, optic neuritis may be treated with corticosteroids to reduce inflammation and speed up recovery . Double vision that occurs during a relapse often improves on its own as the inflammation subsides . In cases where double vision persists, strategies such as wearing an eye patch over one eye or using eyeglasses with special prism lenses can help to realign the images and alleviate the symptom . Treatments for nystagmus are more limited but may include medications like gabapentin or memantine in some cases . Adapting daily activities, such as adjusting lighting and using large print, can also help individuals cope with vision problems .

Cognitive Issues:

Cognitive problems are a common and often underestimated symptom of MS, affecting a significant portion of individuals with the disease . These issues can impact various aspects of thinking, including memory, attention, concentration, information processing speed, learning new things, problem-solving, and understanding language . Many people with MS describe experiencing "brain fog" or "cog fog," a feeling of mental cloudiness or slowness that can make it difficult to think clearly or remember things .

Cognitive problems in MS are a direct consequence of the damage to nerve fibers and the myelin sheath in the brain . This damage can disrupt the transmission of nerve signals, leading to difficulties in processing information efficiently. The severity and specific types of cognitive difficulties can vary widely among individuals with MS . Factors such as fatigue, stress, anxiety, and depression can exacerbate cognitive symptoms . It's important to note that cognitive problems in MS are distinct from dementia and typically involve specific areas of cognitive function rather than a global decline .

Managing cognitive challenges in MS often involves a combination of strategies . Cognitive rehabilitation therapy, which uses exercises and techniques to improve cognitive skills and develop compensatory strategies, can be beneficial . Practical strategies for daily living, such as using memory aids like calendars, notebooks, and electronic reminders, can help compensate for memory difficulties . Breaking down tasks into smaller steps, minimizing distractions, and allowing for extra time to complete tasks can also be helpful . Additionally, addressing other contributing factors like fatigue and mood disorders through appropriate treatments can lead to improvements in cognitive function .

Other Common Symptoms:

Beyond fatigue, mobility issues, vision problems, and cognitive difficulties, individuals with MS can experience a range of other symptoms. Numbness or tingling sensations, also known as paresthesia, are very common and can occur in various parts of the body, including the face, trunk, arms, and legs . Pain is another frequent complaint, which can manifest as neuropathic pain, often described as burning, shooting, or stabbing sensations, or as musculoskeletal pain resulting from muscle stiffness or compensatory movements . Muscle stiffness and spasms, known as spasticity, are also common, particularly affecting the legs and can impact mobility .

Many individuals with MS experience bladder problems, such as increased frequency and urgency of urination, as well as incontinence . Bowel problems, including constipation and bowel incontinence, can also occur . Dizziness and vertigo, a sensation of spinning, are also common . Some individuals may experience speech problems, such as slurred speech (dysarthria) . Mood changes, including depression and anxiety, are also frequently reported in people with MS . Sexual dysfunction is another potential symptom . Some individuals may experience Lhermitte sign, which is an electric-shock sensation that runs down the spine and sometimes into the limbs when bending the neck forward . Emotional lability, including irritability or episodes of uncontrollable laughing or crying (pseudobulbar affect), can also occur . Less frequently, individuals with MS may experience swallowing difficulties (dysphagia) , hearing loss , or seizures (which are rare) . Tremor, or involuntary shaking, is another symptom that can affect some individuals .

The vast array of potential symptoms associated with MS highlights the complexity of diagnosing MS and the highly individualized nature of the condition. The presence and severity of these symptoms can vary greatly from person to person and can also fluctuate over time within the same individual.

Delving into the Causes and Risk Factors of MS

The Interplay of Genetics and Environment:

The precise cause of multiple sclerosis remains elusive, but the prevailing scientific understanding suggests a complex interaction between genetic predisposition and environmental factors . MS is not considered a directly inherited disease in the Mendelian sense, meaning it doesn't follow a simple pattern of inheritance from parent to child based on a single gene . Instead, it is believed that individuals inherit a combination of genes that make them more susceptible to developing the condition, and then exposure to certain environmental triggers may initiate the disease process .

While MS is not directly passed down through generations, having a family history of the disease does increase an individual's risk of developing it . Researchers have identified over 200 genes that are thought to play a role in MS susceptibility, with each gene likely contributing a small effect to the overall risk . The risk of a child developing MS if a parent has the condition is estimated to be around 1.5%, and the risk for a sibling of someone with MS is approximately 2.7% . These figures indicate that while there is a genetic component, it is not the sole determinant of whether someone will develop MS. Environmental factors are believed to be critical in triggering the disease in genetically predisposed individuals. A variety of environmental agents have been implicated, including viral infections, most notably the Epstein-Barr virus (EBV), as well as lifestyle factors such as low vitamin D levels, smoking, and obesity .

The observation that individuals who migrate from a region with a low incidence of MS to one with a high incidence before the age of 15 tend to adopt the risk level of their new environment provides compelling evidence for the significant role of environmental factors in the development of MS. This suggests that exposure to certain environmental agents, particularly during childhood and adolescence, may be crucial in triggering the autoimmune processes that lead to MS in individuals who are genetically susceptible. Research continues to focus on identifying these specific environmental triggers and understanding how they interact with genetic factors to cause the disease.

Established Risk Factors:

Several factors have been consistently identified as increasing the risk of developing multiple sclerosis:

• Age: The onset of MS most commonly occurs between the ages of 20 and 40 .
• Sex: Women are approximately two to three times more likely to develop relapsing-remitting MS than men .
• Family history: Having a parent, sibling, or child with MS increases the risk of developing the disease .
• Certain infections: The Epstein-Barr virus (EBV), which causes infectious mononucleosis, has been strongly linked to an increased risk of MS .
• Race/Ethnicity: Individuals with white skin, particularly those of Northern European descent, have the highest risk of developing MS .
• Climate/Geography: MS is more prevalent in regions with temperate climates, which are located farther away from the equator .
• Vitamin D: Low levels of vitamin D in the blood and reduced exposure to sunlight have been associated with an increased risk of MS .
• Obesity: Being overweight or obese, particularly during childhood and adolescence, has been linked to a higher risk of developing MS .
• Smoking: Cigarette smoking is a well-established risk factor for MS and is also associated with a more severe disease course and faster progression . Exposure to secondhand smoke may also increase the risk .
• Certain autoimmune diseases: Individuals with other autoimmune conditions, such as thyroid disease, pernicious anemia, psoriasis, type 1 diabetes, or inflammatory bowel disease, may have a slightly increased risk of developing MS .
• Gut microbiome: Emerging research suggests that differences in the gut microbiome may be associated with MS risk, but further studies are needed to clarify this connection .

The identification of several modifiable risk factors for MS, including vitamin D levels, obesity, and smoking , presents opportunities for potential prevention strategies and lifestyle interventions aimed at reducing the risk of developing the disease or managing its progression. Public health initiatives promoting smoking cessation, maintaining a healthy weight, and ensuring adequate vitamin D levels may play a role in mitigating MS risk at a population level.

Navigating Treatment Options for MS

Disease-Modifying Therapies (DMTs):

Disease-Modifying Therapies (DMTs) represent the cornerstone of treatment for relapsing forms of multiple sclerosis, which include Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), and active Secondary Progressive MS (SPMS) . The primary goals of DMTs are to reduce the frequency and severity of clinical relapses, slow down the accumulation of disability over time, and limit the development of new lesions or damage within the central nervous system . A variety of DMTs are currently available, and they differ in their mechanisms of action, effectiveness, and routes of administration. These therapies can be administered through self-injection, taken orally as pills or capsules, or given via intravenous infusion at a medical facility .

Examples of commonly used DMTs include interferon beta-1a (available under brand names like Avonex and Rebif), glatiramer acetate (Copaxone), dimethyl fumarate (Tecfidera), teriflunomide (Aubagio), fingolimod (Gilenya), cladribine (Mavenclad), ocrelizumab (Ocrevus), and natalizumab (Tysabri), among many others . Notably, ocrelizumab is also approved for the treatment of primary progressive MS (PPMS) , and siponimod (Mayzent) is approved for non-active secondary progressive MS (SPMS) . It is important to be aware that each DMT has its own specific profile of potential side effects and long-term risks. These should be carefully discussed with a healthcare provider before starting treatment .

The increasing availability of a wide range of approved DMTs has significantly transformed the management of MS. This growing armamentarium of therapies allows for a more tailored approach to treatment, taking into account the specific type of MS, disease activity, individual patient characteristics, and preferences. The development of new DMTs continues to be a major focus of research, offering hope for even more effective and well-tolerated treatments in the future.

Symptom Management Techniques:

In addition to disease-modifying therapies, a variety of techniques are employed to manage the wide range of symptoms associated with MS and to improve the overall quality of life for affected individuals . These approaches are tailored to address specific symptoms and can include both pharmacological and non-pharmacological interventions.

For fatigue, which is a common and often debilitating symptom, medications such as amantadine, modafinil, and armodafinil may be prescribed to help improve energy levels . Lifestyle strategies, including pacing activities, ensuring adequate rest, and managing sleep disturbances, are also crucial in combating fatigue . Walking difficulties can be addressed through physical therapy to improve strength and balance, the use of assistive devices like canes, walkers, or wheelchairs, and in some cases, medications such as dalfampridine, which can help increase walking speed . Spasticity, or muscle stiffness and spasms, may be managed with muscle relaxants like baclofen and tizanidine, as well as through physical therapy and in some instances, injections of botulinum toxin (Botox) . Pain, a frequent symptom in MS, can be treated with various medications, including anticonvulsants, antidepressants, and analgesics, as well as through non-pharmacological methods such as physical therapy, Transcutaneous Electrical Nerve Stimulation (TENS), and complementary therapies like acupuncture and yoga . Bladder and bowel problems can be managed through lifestyle modifications, medications, intermittent catheterization, and in some cases, nerve stimulation therapies . For cognitive issues, which can affect memory, attention, and processing speed, cognitive rehabilitation therapy and the use of compensatory strategies are often recommended . Finally, emotional issues, such as depression and anxiety, can be addressed through counseling, various forms of therapy (like Cognitive Behavioral Therapy or Acceptance and Commitment Therapy), support groups, and medications like antidepressants and anti-anxiety drugs .

Effective symptom management in MS often requires a collaborative and multidisciplinary approach . This may involve a team of healthcare professionals, including neurologists, physical therapists, occupational therapists, speech therapists, psychologists, and other specialists, working together to develop an individualized treatment plan that addresses the specific needs and challenges of each person living with MS.

Recent Advancements in MS Research

Emerging Therapies and Drugs in Development:

The field of MS research is dynamic, with ongoing efforts focused on developing new and more effective therapies for all forms of the disease, including the more challenging progressive forms . In recent years, several novel disease-modifying therapies have received regulatory approval, such as ocrelizumab (Ocrevus), siponimod (Mayzent), cladribine (Mavenclad), ofatumumab (Kesimpta), and ublituximab (Briumvi) . These newer DMTs often target different aspects of the immune system and offer additional options for individuals with relapsing forms of MS.

Furthermore, a number of investigational drugs are currently in various stages of clinical development. For instance, tolebrutinib, an oral medication that inhibits Bruton's tyrosine kinase (BTK), has shown promising results in clinical trials for the treatment of non-relapsing secondary-progressive MS (nrSPMS) and has received Breakthrough Therapy designation from regulatory agencies . Fenebrutinib, another BTK inhibitor, is also in Phase 3 clinical trials and is being investigated for its potential to treat both relapsing and primary progressive forms of MS . Additionally, intranasal foralumab, a monoclonal antibody, is being explored as a treatment for non-active SPMS .

The significant focus on developing treatments for progressive forms of MS represents a critical area of research. Currently, there are fewer approved therapies for progressive MS compared to relapsing forms, making the development of new treatments for PPMS and SPMS a high priority in the MS research community. The emergence of drugs like ocrelizumab for PPMS and the ongoing investigation of other agents offer hope for improving outcomes for individuals with these more challenging forms of the disease.

Research on Remyelination and Neuroprotection:

A central goal in MS research is the development of therapies that can promote the repair of damaged myelin (remyelination) and protect nerve cells from further damage (neuroprotection) . While current DMTs primarily focus on modulating the immune system to reduce inflammation and prevent further demyelination, therapies that can actively repair myelin or protect neurons could potentially reverse some of the neurological deficits caused by MS.

Several promising avenues of research are being explored in this area. Clemastine fumarate, an antihistamine available over the counter, has shown potential in promoting remyelination in clinical trials involving individuals with relapsing forms of MS . PIPE-307, a selective antagonist of the M1 muscarinic receptor, is currently in Phase 2 clinical trials for relapsing-remitting MS and has demonstrated encouraging preclinical results in stimulating the differentiation of oligodendrocyte precursor cells into myelin-producing oligodendrocytes . Researchers are also investigating the potential of various other molecules and pathways to promote remyelination and neuroprotection. These include exploring the role of estriol, a pregnancy hormone, in myelin repair and neuroprotection , as well as investigating pathways like NLRX1 for their neuroprotective effects in experimental models of MS .

The ongoing research into remyelination therapies represents a significant step towards potentially reversing the damage caused by MS, rather than just slowing its progression. If successful, these therapies could lead to improvements in neurological function and a reduction in long-term disability for people living with MS.

Potential of Stem Cell Therapy:

Stem cell therapy, particularly autologous hematopoietic stem cell transplantation (aHSCT), is being investigated as a potential treatment option for certain individuals with highly active or aggressive forms of MS . aHSCT is a complex procedure that aims to "reset" the patient's immune system to stop it from attacking the myelin sheath. This involves collecting hematopoietic stem cells (cells that can develop into all types of blood cells, including immune cells) from the patient's own bone marrow or blood . The patient then undergoes high-dose chemotherapy to eliminate their existing immune system, followed by the reinfusion of their previously collected stem cells, which then migrate to the bone marrow and regenerate a new immune system .

While aHSCT has shown promising results in some clinical trials for reducing disease activity and disability progression in carefully selected patients with aggressive MS, it is an intensive procedure with potential risks and serious complications . Research is ongoing to better understand which individuals with MS are most likely to benefit from aHSCT and to compare its safety and effectiveness to that of other available MS therapies . Another type of stem cell therapy, using mesenchymal stem cells (MSCs), is also being explored for its potential to modulate the immune system and promote repair in MS . However, more research is needed to determine the efficacy and long-term benefits of MSC therapy for MS.

Although aHSCT holds promise for certain individuals with highly active MS , it is still considered an experimental treatment for MS in many centers, and the decision to undergo this procedure should be made in consultation with a healthcare professional who specializes in MS and stem cell transplantation, carefully considering the potential risks and benefits.

The Role of Personalized Medicine in MS Treatment:

The field of MS treatment is increasingly moving towards a more personalized approach, often referred to as precision medicine . This approach aims to tailor treatment strategies to the unique characteristics of each individual with MS, taking into account not only their specific symptoms and disease course but also their genetic makeup, lifestyle, and various biological markers (biomarkers) .

The application of personalized medicine in MS involves using advanced technologies, such as genomics (the study of genes), proteomics (the study of proteins), metabolomics (the study of metabolites), and sophisticated imaging techniques, to identify specific biomarkers and disease subtypes . Researchers are working to develop predictive models that can integrate clinical data, biological markers, and imaging findings to better understand an individual's prognosis and predict how they might respond to different treatment options . For example, blood biomarkers, such as the level of neurofilament light chain (NfL), a protein that indicates nerve damage, are being investigated for their potential to predict the likelihood of future disease activity and disability progression .

The goal of personalized medicine in MS is to move away from a one-size-fits-all approach to treatment and instead develop targeted therapies that can modulate specific immune pathways or address underlying disease mechanisms in a way that is most effective for each individual . This approach has the potential to lead to earlier and more accurate diagnoses, better prediction of disease course, improved treatment efficacy, and a reduction in the risk of adverse effects by selecting the most appropriate therapy for each person at the right time . While the implementation of personalized medicine in MS still faces challenges, such as the complexity of the disease and the need for further research to validate biomarkers and develop targeted therapies, it holds significant promise for revolutionizing the way MS is managed in the future.

Living Well with MS: Practical Tips and Coping Strategies

Lifestyle Adjustments:
Living well with MS involves more than just medical treatments; making positive lifestyle adjustments can significantly impact overall health and well-being . While there is no specific diet proven to alter the course of MS, a healthy, balanced diet that includes plenty of fruits, vegetables, whole grains, lean protein sources, and healthy fats is generally recommended . Maintaining a healthy body weight is also important, as obesity has been linked to increased MS activity . Regular exercise is highly beneficial for individuals with MS, helping to improve strength, balance, coordination, cardiovascular health, mood, and even bowel and bladder function . Gentle forms of exercise like yoga, Tai Chi, and swimming are often well-tolerated . Getting sufficient restful sleep is crucial for managing fatigue, a common and often debilitating symptom of MS . Establishing a consistent sleep schedule and practicing good sleep hygiene can help improve sleep quality . Managing stress is also vital, as stress can sometimes trigger or worsen MS symptoms. Techniques such as mindfulness, meditation, yoga, Tai Chi, engaging in hobbies, and spending time with loved ones can be helpful stress-reduction strategies . For individuals who smoke, quitting is strongly recommended due to the negative impact of smoking on MS progression . Maintaining adequate levels of vitamin D may also be beneficial . Finally, for those who experience heat sensitivity, taking measures to stay cool, such as using cooling vests or avoiding hot environments, can help manage symptoms .

The emphasis on a holistic approach to wellness for individuals with MS highlights the importance of integrating healthy lifestyle choices into the overall management plan. These adjustments, in conjunction with medical treatments, can empower individuals to take an active role in managing their condition and improving their quality of life.

Coping Mechanisms for Daily Challenges:

Living with MS can present various daily challenges, and developing effective coping mechanisms is essential for navigating these difficulties. Making simple accommodations in the home and workplace, such as keeping frequently used items within easy reach or using voice-to-text software, can help conserve energy and reduce physical demands . Tracking symptoms in a journal can help individuals identify patterns, triggers, and the effectiveness of different management strategies . Learning to prioritize tasks and pace activities throughout the day is crucial for managing fatigue and preventing overexertion . Utilizing assistive devices, such as walking aids or adaptive equipment for daily tasks, can enhance independence and safety . Reaching out for help and building a strong support network of family, friends, and support groups can provide emotional comfort, practical assistance, and valuable insights from others living with MS . Cultivating a positive attitude and maintaining a sense of humor can also be powerful tools for coping with the challenges of living with a chronic condition .

Building a robust support network is an invaluable resource for individuals living with MS. Connecting with others who understand the unique challenges of this condition can provide emotional validation, practical advice, and a sense of belonging to a community. Sharing experiences and coping strategies can be both therapeutic and empowering, helping to reduce feelings of isolation and fostering a greater sense of control over the disease.

Finding Support: Resources and Further Information on MS

National and International MS Organizations:

A wealth of resources and support is available for individuals affected by multiple sclerosis and their families. Several national and international organizations are dedicated to providing information, support, funding research, and advocating for the rights of people with MS. The existence of this extensive network of national and international organizations provides a strong foundation of support for individuals and families navigating life with MS. These organizations offer a wealth of reliable information and can help connect people with the resources they need.

• The National Multiple Sclerosis Society (NMSS) is a leading organization in the United States offering a wide range of resources, including information on diagnosis, treatment, research, wellness strategies, and support services. They also provide a helpline and can connect individuals with local chapters and support groups . Their website is www.nationalmssociety.org, and their helpline can be reached at 1-800-344-4867.
• The Multiple Sclerosis Association of America (MSAA) is another national non-profit organization in the US dedicated to improving the lives of individuals with MS through vital services and support, including a helpline, equipment assistance, and MRI funding . Their website is www.mymsaa.org, and they can be contacted at 1-800-532-7667.
• In the United Kingdom, the MS Society UK is the largest charity for people affected by MS, providing information, support, funding research, and campaigning for social and political change . Their website is www.mssociety.org.uk, and their helpline number is 0808 800 8000.
• The MS International Federation (MSIF) is a global network linking MS organizations around the world, facilitating collaboration, information sharing, and advocating for people with MS on an international level . Their website is www.msif.org.
• MS Focus (Multiple Sclerosis Foundation) in the US provides free services that address the critical needs of people with MS and their families, including support and educational programs . Their website is www.msfocus.org, and they can be reached at 1-800-673-6287.
• The MS Trust in the UK offers information and support for anyone affected by MS, as well as resources for healthcare professionals and funding for research . Their website is www.mstrust.org.uk, and their helpline number is 0800 032 38 39.

Information on Support Groups and Online Communities:

Connecting with others who are also living with MS can be incredibly beneficial, offering a sense of community, understanding, and shared experience . Support groups provide a safe and supportive environment where individuals can share their experiences, discuss coping strategies, and learn from others facing similar challenges . Many national MS organizations, as well as local chapters, offer in-person and online support groups . Online communities and forums can also be valuable resources, providing opportunities for peer support and information exchange for those who may not have access to in-person groups or prefer the convenience of online interaction . These online platforms can connect individuals from around the world, fostering a sense of global community among those affected by MS . Healthcare providers and local MS treatment centers can often provide information about support groups in a specific geographic area .

The availability of both in-person and online support options underscores the importance of peer support in the MS community. Connecting with others who have firsthand experience of living with MS can provide invaluable emotional and practical support, helping individuals feel less alone and more empowered in managing their condition.

Conclusion

Multiple Sclerosis is a complex and highly variable neurological disease that impacts the central nervous system. While the exact cause remains under investigation, it is understood to be a result of an interplay between genetic susceptibility and environmental factors. Characterized by the immune system's attack on the protective myelin sheath of nerve fibers, MS can lead to a wide range of symptoms affecting mobility, sensation, vision, cognition, and other bodily functions. The disease follows several distinct courses, including relapsing-remitting, primary progressive, and secondary progressive MS, each with its own pattern of symptom progression and severity.

Significant advancements have been made in the treatment of MS, particularly with the development of numerous disease-modifying therapies that can help reduce relapse rates and slow disease progression in relapsing forms of MS. Research continues to forge ahead, exploring new therapeutic targets, investigating promising strategies for remyelination and neuroprotection, and refining the role of stem cell therapy. The future of MS management also holds the potential for more personalized approaches, tailoring treatments based on individual disease characteristics and biomarkers.

Living well with MS involves a comprehensive approach that extends beyond medical treatments. Lifestyle adjustments, such as maintaining a healthy diet, engaging in regular exercise, managing stress, and getting adequate sleep, play a crucial role in overall well-being. Developing effective coping mechanisms for daily challenges and building a strong support network are also essential for navigating life with MS. Numerous national and international organizations are dedicated to providing resources, information, and support for individuals affected by MS and their families, ensuring that no one has to face this journey alone.

Works cited

1. What is Multiple Sclerosis? - National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/understanding-ms/what-is-ms
2. Multiple Sclerosis (MS) | Johns Hopkins Medicine, accessed March 28, 2025, https://www.hopkinsmedicine.org/health/conditions-and-diseases/multiple-sclerosis-ms
3. What is Multiple Sclerosis (MS)? - MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/about-ms/what-is-ms
4. www.mayoclinic.org, accessed March 28, 2025, https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/symptoms-causes/syc-20350269#:~:text=Multiple%20sclerosis%20is%20a%20disease,nerve%20fibers%2C%20known%20as%20myelin.
5. Multiple sclerosis - Symptoms and causes - Mayo Clinic, accessed March 28, 2025, https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/symptoms-causes/syc-20350269
6. Understanding Multiple Sclerosis | Brain Institute - OHSU, accessed March 28, 2025, https://www.ohsu.edu/brain-institute/understanding-multiple-sclerosis
7. Multiple Sclerosis (MS): What It Is, Symptoms & Treatment - Cleveland Clinic, accessed March 28, 2025, https://my.clevelandclinic.org/health/diseases/17248-multiple-sclerosis
8. www.nationalmssociety.org, accessed March 28, 2025, https://www.nationalmssociety.org/for-professionals/for-healthcare-professionals/general-ms-information#:~:text=Multiple%20sclerosis%20(MS)%20is%20a,axons%20themselves%20are%20also%20damaged.
9. About Multiple Sclerosis (MS) - National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/for-professionals/for-healthcare-professionals/general-ms-information
10. Multiple Sclerosis | National Institute of Neurological Disorders and Stroke, accessed March 28, 2025, https://www.ninds.nih.gov/health-information/disorders/multiple-sclerosis
11. National Multiple Sclerosis Society, accessed March 28, 2025, https://rarediseases.org/organizations/national-multiple-sclerosis-society/
12. What is multiple sclerosis? An expert explains - Mayo Clinic, accessed March 28, 2025, https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/multimedia/what-is-multiple-sclerosis-an-expert-explains/vid-20522476
13. Mayo Clinic Q and A: Understanding multiple sclerosis, accessed March 28, 2025, https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-q-and-a-understanding-multiple-sclerosis/
14. Mayo Clinic Explains Multiple Sclerosis - YouTube, accessed March 28, 2025, https://www.youtube.com/watch?v=Z1ibVlGflPs
15. Mayo Clinic Minute: What is MS? - YouTube, accessed March 28, 2025, https://www.youtube.com/watch?v=XKHMuFmyuo8
16. Relapsing-Remitting Multiple Sclerosis (RRMS) - National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/understanding-ms/what-is-ms/types-of-ms/relapse-remitting-ms
17. Relapsing Remitting MS (RRMS) - MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/about-ms/types-of-ms/relapsing-remitting-ms
18. Understanding the Types and Symptoms of Multiple Sclerosis - Shepherd Center, accessed March 28, 2025, https://www.shepherd.org/programs/outpatient/multiple-sclerosis/what-is-ms/types
19. Types of Multiple Sclerosis | National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/understanding-ms/what-is-ms/types-of-ms
20. The Different Types of Multiple Sclerosis (MS) Explained - WebMD, accessed March 28, 2025, https://www.webmd.com/multiple-sclerosis/multiple-sclerosis-understanding-the-differences-in-ms
21. Types of Multiple Sclerosis | MSAA, accessed March 28, 2025, https://mymsaa.org/ms-information/overview/types/
22. Types of MS - Relapsing, Primary & Secondary - MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/about-ms/types-of-ms
23. www.mssociety.org.uk, accessed March 28, 2025, https://www.mssociety.org.uk/about-ms/types-of-ms/primary-progressive-ms#:~:text=Primary%20progressive%20MS%20(PPMS)%20is,or%20no%20relapses%20with%20PPMS.
24. Primary Progressive Multiple Sclerosis (PPMS): Symptoms - Cleveland Clinic, accessed March 28, 2025, https://my.clevelandclinic.org/health/diseases/14202-primary-progressive-multiple-sclerosis-ppms
25. www.shepherd.org, accessed March 28, 2025, https://www.shepherd.org/programs/outpatient/multiple-sclerosis/what-is-ms/types#:~:text=Secondary%2DProgressive%20MS%20(SPMS)%3A,worsening%20symptoms%20and%20neurologic%20function.
26. Secondary Progressive Multiple Sclerosis (SPMS) - National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/understanding-ms/what-is-ms/types-of-ms/secondary-progressive-ms
27. What Is Secondary Progressive MS? (SPMS), accessed March 28, 2025, https://www.mssociety.org.uk/about-ms/types-of-ms/secondary-progressive-ms
28. Secondary progressive MS - MS Trust, accessed March 28, 2025, https://mstrust.org.uk/a-z/secondary-progressive-ms
29. Secondary-Progressive Multiple Sclerosis - Cedars-Sinai, accessed March 28, 2025, https://www.cedars-sinai.org/health-library/diseases-and-conditions/s/secondary-progressive-multiple-sclerosis.html
30. Clinically isolated syndrome (CIS) - MS Trust, accessed March 28, 2025, https://mstrust.org.uk/a-z/clinically-isolated-syndrome-cis
31. Clinically isolated syndrome (CIS) - MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/about-ms/types-of-ms/clinically-isolated-syndrome-cis
32. Clinically Isolated Syndrome | Cedars-Sinai, accessed March 28, 2025, https://www.cedars-sinai.org/health-library/diseases-and-conditions/c/clinically-isolated-syndrome.html
33. Clinically Isolated Syndrome (CIS) | National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/understanding-ms/what-is-ms/clinically-isolated-syndrome-cis
34. The radiologically isolated syndrome: revised diagnostic criteria - PMC - PubMed Central, accessed March 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11004931/
35. Radiologically Isolated syndrome (RIS) - Cleveland Clinic, accessed March 28, 2025, https://my.clevelandclinic.org/departments/neurological/depts/multiple-sclerosis/ms-approaches/radiologically-isolated-syndrome
36. Radiologically Isolated Syndrome: A Review for Neuroradiologists - PMC - PubMed Central, accessed March 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7583110/
37. Radiologically Isolated Syndrome (RIS) - Cedars-Sinai, accessed March 28, 2025, https://www.cedars-sinai.org/health-library/diseases-and-conditions/r/radiologically-isolated-syndrome-ris.html
38. Multiple sclerosis - NHS, accessed March 28, 2025, https://www.nhs.uk/conditions/multiple-sclerosis/
39. Early Signs of MS You Shouldn't Ignore | Mass General Brigham, accessed March 28, 2025, https://www.massgeneralbrigham.org/en/about/newsroom/articles/early-signs-ms
40. Early Signs of MS - Common Signs and Symptoms - MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/about-ms/signs-and-symptoms/early-signs-of-ms
41. Early symptoms of MS | MS Trust, accessed March 28, 2025, https://mstrust.org.uk/information-support/ms-symptoms-diagnosis/early-symptoms
42. What is multiple sclerosis (MS) fatigue? - MyHealth Alberta, accessed March 28, 2025, https://myhealth.alberta.ca/Alberta/Pages/multiple-sclerosis-fatigue.aspx
43. About MS Fatigue - Causes & Management, accessed March 28, 2025, https://www.mssociety.org.uk/about-ms/signs-and-symptoms/fatigue/about-fatigue
44. Fatigue | MS Trust, accessed March 28, 2025, https://mstrust.org.uk/a-z/fatigue
45. MS and Fatigue Fact Sheet | Cleveland Clinic, accessed March 28, 2025, https://my.clevelandclinic.org/departments/neurological/depts/multiple-sclerosis/ms-approaches/ms-and-fatigue
46. Fatigue | MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/about-ms/signs-and-symptoms/fatigue
47. Walking (Gait) Difficulties and MS | National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/understanding-ms/what-is-ms/ms-symptoms/walking-gait-difficulties
48. MS and Walking Difficulties - Multiple Sclerosis Foundation, accessed March 28, 2025, https://msfocus.org/Magazine/Magazine-Items/Posted/MS-and-Walking-Difficulties.aspx?lang=en-US
49. Smoking and Multiple Sclerosis - Multiple Sclerosis Centers of Excellence - VA.gov, accessed March 28, 2025, https://www.va.gov/MS/TREATING_MS/Whole_Health/Smoking_and_MS.asp
50. Smoking and MS | MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/living-with-ms/physical-and-mental-health/smoking-and-ms
51. Smoking and MS - MS Trust, accessed March 28, 2025, https://mstrust.org.uk/a-z/smoking
52. Smoking and MS: Unraveling the Links, Impact on Disease Progression, and Cessation Strategies - Cleveland Clinic, accessed March 28, 2025, https://my.clevelandclinic.org/departments/neurological/depts/multiple-sclerosis/ms-approaches/ms-and-smoking
53. Obesity | MS Trust, accessed March 28, 2025, https://mstrust.org.uk/a-z/obesity
54. Multiple sclerosis - Diagnosis and treatment - Mayo Clinic, accessed March 28, 2025, https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/diagnosis-treatment/drc-20350274
55. How is MS treated? | MS Trust, accessed March 28, 2025, https://mstrust.org.uk/information-support/ms-drugs-treatments/how-is-ms-treated
56. Fatigue | MSAA - Multiple Sclerosis Association of America, accessed March 28, 2025, https://mymsaa.org/ms-information/symptoms/fatigue/
57. MS Fatigue: Causes, Symptoms, and Treatments - Healthline, accessed March 28, 2025, https://www.healthline.com/health/multiple-sclerosis/ms-fatigue
58. Walking difficulties | MS Trust, accessed March 28, 2025, https://mstrust.org.uk/a-z/walking-difficulties
59. 5 Tips for Living Better with MS: Patients and Caregivers | Johns Hopkins Medicine, accessed March 28, 2025, https://www.hopkinsmedicine.org/health/conditions-and-diseases/multiple-sclerosis-ms/5-tips-for-living-better-with-ms-patients-and-caregivers
60. 10 Tips for Living with Multiple Sclerosis - AmeriPharma® Specialty Care, accessed March 28, 2025, https://ameripharmaspecialty.com/multiple-sclerosis/10-tips-for-living-with-multiple-sclerosis/
61. Lifestyle choices | MS Trust, accessed March 28, 2025, https://mstrust.org.uk/information-support/wellbeing-ms/lifestyle-choices
62. 8 Tips for Managing Multiple Sclerosis (MS) - Healthline, accessed March 28, 2025, https://www.healthline.com/health/multiple-sclerosis/daily-tips-managing-ms
63. Managing MS Fatigue - Help & Support, accessed March 28, 2025, https://www.mssociety.org.uk/about-ms/signs-and-symptoms/fatigue/managing-fatigue
64. MS Fatigue: Why Multiple Sclerosis Makes You Tired & 5 Tips to Cope - WebMD, accessed March 28, 2025, https://www.webmd.com/multiple-sclerosis/ms-related-fatigue
65. Diet and MS | MS Trust, accessed March 28, 2025, https://mstrust.org.uk/information-support/diet-ms
66. Balance and Walking - Symptoms - MS Australia, accessed March 28, 2025, https://www.msaustralia.org.au/symptom/balance-and-walking/
67. Balance, gait, and falls in multiple sclerosis - PubMed, accessed March 28, 2025, https://pubmed.ncbi.nlm.nih.gov/30482317/
68. Living With Multiple Sclerosis | Patient Education - UCSF Health, accessed March 28, 2025, https://www.ucsfhealth.org/education/living-with-multiple-sclerosis
69. Exercise and multiple sclerosis - Mayo Clinic, accessed March 28, 2025, https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/expert-answers/exercise-and-multiple-sclerosis/faq-20094108
70. Treating walking difficulties with orthotics | MS Trust, accessed March 28, 2025, https://mstrust.org.uk/news/expert/using-orthoses-improve-walking-difficulties
71. Multiple Sclerosis (MS) - Symptoms and Causes - Penn Medicine, accessed March 28, 2025, https://www.pennmedicine.org/for-patients-and-visitors/patient-information/conditions-treated-a-to-z/multiple-sclerosis-ms
72. www.mssociety.org.uk, accessed March 28, 2025, https://www.mssociety.org.uk/about-ms/signs-and-symptoms/eyes-and-sight#:~:text=MS%20can%20also%20have%20an,your%20vision%20isn't%20affected.
73. Visual Disturbances - MS Australia, accessed March 28, 2025, https://www.msaustralia.org.au/symptom/visual-disturbances/
74. MS eye and vision problems, accessed March 28, 2025, https://www.mssociety.org.uk/about-ms/signs-and-symptoms/eyes-and-sight
75. Vision Problems & Multiple Sclerosis | National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/understanding-ms/what-is-ms/ms-symptoms/vision-problems
76. MS Vision Issues | Multiple Sclerosis - MS International Federation, accessed March 28, 2025, https://www.msif.org/about-ms/symptoms-of-ms/vision-issues/
77. Visual Disorders | MSAA - Multiple Sclerosis Association of America, accessed March 28, 2025, https://mymsaa.org/ms-information/symptoms/visual-disorders/
78. Recognizing & Managing MS Vision Issues - National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/news-and-magazine/momentum-magazine/living-well/recognizing-and-managing-vision-symptoms
79. Vision Problems from Multiple Sclerosis - Optometrists.org, accessed March 28, 2025, https://www.optometrists.org/vision-therapy/neuro-optometry/vision-problems-from-multiple-sclerosis/
80. Cognition Problems (Thinking and Memory) - MS Australia, accessed March 28, 2025, https://www.msaustralia.org.au/symptom/cognition/
81. Thinking and memory problems | MS Trust, accessed March 28, 2025, https://mstrust.org.uk/information-support/health-wellbeing/thinking-and-memory-problems
82. Memory and thinking | MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/about-ms/signs-and-symptoms/memory-and-thinking
83. Cognitive problems in MS | MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/about-ms/signs-and-symptoms/memory-and-thinking/cognitive-problems-in-ms
84. Emotional and cognitive changes - MS International Federation, accessed March 28, 2025, https://www.msif.org/about-ms/symptoms-of-ms/cognition-and-emotional-changes/
85. Obesity Affects Disease Activity and Progression, Cognitive Functioning, and Quality of Life in People With Multiple Sclerosis | Neurology Neuroimmunology & Neuroinflammation, accessed March 28, 2025, https://www.neurology.org/doi/10.1212/NXI.0000000000200334
86. Obesity Accelerates Disease Progression in Patients With Multiple Sclerosis, accessed March 28, 2025, https://www.neurologylive.com/view/obesity-accelerates-disease-progression-patients-ms
87. Cognitive Symptoms in Multiple Sclerosis: Screening and Treatment - Healthline, accessed March 28, 2025, https://www.healthline.com/health/multiple-sclerosis/manage-cognitive-changes
88. Cognitive Health & Functioning with MS | National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/managing-ms/living-with-ms/cognitive-health
89. The Role of Diet and Lifestyle in Managing Multiple Sclerosis | Rush, accessed March 28, 2025, https://www.rush.edu/news/role-diet-and-lifestyle-managing-multiple-sclerosis
90. Multiple Sclerosis and Mental Health: 3 Common Challenges | Johns Hopkins Medicine, accessed March 28, 2025, https://www.hopkinsmedicine.org/health/conditions-and-diseases/multiple-sclerosis-ms/multiple-sclerosis-and-mental-health-3-common-challenges
91. Multiple Sclerosis Cure: How Close We Are and New Treatments - Healthline, accessed March 28, 2025, https://www.healthline.com/health/multiple-sclerosis/new-research-treatments
92. Successfully Managing Pain in Multiple Sclerosis - VA.gov, accessed March 28, 2025, https://www.va.gov/MS/Veterans/symptoms_of_MS/Successfully_Managing_Pain_in_Multiple_Sclerosis.asp
93. Pain and MS - Causes & Treatment - MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/about-ms/signs-and-symptoms/pain
94. Multiple Sclerosis and Sleep - WebMD, accessed March 28, 2025, https://www.webmd.com/multiple-sclerosis/ms-taking-control-sleep
95. Urinary tract infections (UTIs) - MS Trust, accessed March 28, 2025, https://mstrust.org.uk/a-z/urinary-tract-infection-uti
96. Treatments & Medications for MS - National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/managing-ms/treating-ms/treatments-and-medications
97. Neurogenic bladder and bowel management - Mayo Clinic, accessed March 28, 2025, https://www.mayoclinic.org/tests-procedures/neurogenic-bladder-bowel-management/about/pac-20394763
98. Bladder and bowel problems - MS Trust, accessed March 28, 2025, https://mstrust.org.uk/a-z/bladder-and-bowel-problems
99. Managing bladder problems | MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/about-ms/signs-and-symptoms/bladder/managing-bladder-problems
100. Maintaining a Healthy Lifestyle with Multiple Sclerosis - UCSF Health, accessed March 28, 2025, https://www.ucsfhealth.org/education/maintaining-a-healthy-lifestyle-with-multiple-sclerosis
101. Lifestyle Changes That May Help Slow MS Progression - WebMD, accessed March 28, 2025, https://www.webmd.com/multiple-sclerosis/rrms-changes-slow-progression
102. Easy and Common Tips for Good Sleep - Multiple Sclerosis Centers of Excellence - VA.gov, accessed March 28, 2025, https://www.va.gov/MS/Veterans/symptoms_of_MS/Easy_and_Common_Tips_for_Good_Sleep.asp
103. Rehabilitation and Multiple Sclerosis - National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/managing-ms/treating-ms/rehabilitation
104. Rehabilitation Therapies for MS, accessed March 28, 2025, https://www.nationalmssociety.org/for-professionals/for-healthcare-professionals/managing-and-treating-ms/rehabilitation-therapies
105. Coping Strategies for People with Multiple Sclerosis - VA.gov, accessed March 28, 2025, https://www.va.gov/MS/TREATING_MS/Whole_Health/Coping_Strategies_for_People_with_MS.asp
106. Emotional Well-Being and Multiple Sclerosis - National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/managing-ms/living-with-ms/emotional-well-being
107. Anxiety, Stress and MS - Managing Stress, accessed March 28, 2025, https://www.mssociety.org.uk/living-with-ms/physical-and-mental-health/mental-health/stress-and-anxiety
108. Stress and MS - MS Trust, accessed March 28, 2025, https://mstrust.org.uk/a-z/stress
109. Managing stress in multiple sclerosis - MS Trust, accessed March 28, 2025, https://mstrust.org.uk/news/expert/managing-stress-multiple-sclerosis
110. Multiple Sclerosis - Sepsis Alliance, accessed March 28, 2025, https://www.sepsis.org/sepsisand/multiple-sclerosis/
111. Multiple Sclerosis Foundation - Is There a Connection Between MS and Obesity?, accessed March 28, 2025, https://msfocusmagazine.org/Magazine/Magazine-Items/Exclusive-Content/2022/Is-There-a-Connection-Between-MS-and-Obesity
112. Multiple sclerosis and obesity: The role of adipokines - Frontiers, accessed March 28, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1038393/full
113. Disease Modifying Therapies for Multiple Sclerosis - VA.gov, accessed March 28, 2025, https://www.va.gov/MS/TREATING_MS/Disease_Modifying_Therapies_for_Multiple_Sclerosis.asp
114. Disease Modifying Therapies For MS - DMTs, accessed March 28, 2025, https://www.mssociety.org.uk/living-with-ms/treatments-and-therapies/disease-modifying-therapies
115. Disease Modification & DMT's for MS - National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/for-professionals/for-healthcare-professionals/managing-and-treating-ms/disease-modification
116. Multiple Sclerosis: Overview of Disease-Modifying Agents - PMC - PubMed Central, accessed March 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4197902/
117. www.va.gov, accessed March 28, 2025, https://www.va.gov/MS/RESOURCES/Brochures/NMSS_flyer_modifying_therapy.pdf
118. Ocrelizumab (Ocrevus) - DMTs for MS - MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/living-with-ms/treatments-and-therapies/disease-modifying-therapies/ocrelizumab
119. Comparing Medicines to Help Patients with Multiple Sclerosis Feel Less Fatigued—The TRIUMPHANT-MS Study - NCBI, accessed March 28, 2025, https://www.ncbi.nlm.nih.gov/books/NBK602816/
120. Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews - PMC, accessed March 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6353175/
121. mymsaa.org, accessed March 28, 2025, https://mymsaa.org/news/whats-new-in-ms-research-january-2025/#:~:text=In%20December%202024%2C%20the%20Food,progressive%20multiple%20sclerosis%20(nrSPMS).
122. Research News and Progress - National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/understanding-ms/ms-research/research-news-progress
123. What's New in MS Research - January 2025 | MSAA, accessed March 28, 2025, https://mymsaa.org/news/whats-new-in-ms-research-january-2025/
124. Multiple Sclerosis Research News - ScienceDaily, accessed March 28, 2025, https://www.sciencedaily.com/news/health_medicine/multiple_sclerosis/
125. What's New in MS Research - September 2024 - Multiple Sclerosis Association of America, accessed March 28, 2025, https://mymsaa.org/news/whats-new-in-ms-research-september-2024/
126. Emerging treatments for multiple sclerosis - Mayo Clinic, accessed March 28, 2025, https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/expert-answers/emerging-treatments-for-ms/faq-20096786
127. Multiple Sclerosis: Moving Towards a Cure | Brown University Health, accessed March 28, 2025, https://www.brownhealth.org/be-well/multiple-sclerosis-moving-towards-cure
128. Future Strategies for MS Therapies - Multiple Sclerosis - NCBI Bookshelf, accessed March 28, 2025, https://www.ncbi.nlm.nih.gov/books/NBK222403/
129. Emerging research and treatments - MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/research/explore-our-research/emerging-research-and-treatments
130. New Multiple Sclerosis Medications Being Developed - BrainWise Media, accessed March 28, 2025, https://brainwisemedia.com/new-multiple-sclerosis-medications-being-developed/
131. Explore treatments in trials - MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/research/explore-our-research/emerging-research-and-treatments/explore-treatments-in-trials
132. Multiple Sclerosis Clinical Trials - Johns Hopkins Medicine, accessed March 28, 2025, https://www.hopkinsmedicine.org/neurology-neurosurgery/specialty-areas/multiple-sclerosis/clinical-trials
133. Participate in a Clinical Trial - National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/how-you-can-help/get-involved/participate-in-research-studies/participate-in-clinical-trials
134. Evolution of clinical trials in multiple sclerosis - PMC - PubMed Central, accessed March 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6391540/
135. Clinical Trials in the Multiple Sclerosis Clinic - Massachusetts General Hospital, accessed March 28, 2025, https://www.massgeneral.org/neurology/multiple-sclerosis/research/clinical-trials
136. UCSF Multiple Sclerosis Clinical Trials — San Francisco Bay Area, accessed March 28, 2025, https://clinicaltrials.ucsf.edu/multiple-sclerosis
137. Promoting Remyelination in Multiple Sclerosis—Recent Advances - PMC - PubMed Central, accessed March 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3853368/
138. Promoting remyelination in multiple sclerosis - PMC - PubMed Central, accessed March 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7815564/
139. Pipe dream: Remyelination therapy for multiple sclerosis - PNAS, accessed March 28, 2025, https://www.pnas.org/doi/10.1073/pnas.2414324121
140. Remyelination in multiple sclerosis from the miRNA perspective - Frontiers, accessed March 28, 2025, https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2023.1199313/full
141. A recipe for remyelination | Drug Discovery News, accessed March 28, 2025, https://www.drugdiscoverynews.com/a-recipe-for-remyelination-15831
142. Stem Cell Therapy for Multiple Sclerosis - VA.gov, accessed March 28, 2025, https://www.va.gov/MS/TREATING_MS/Whole_Health/Stem_Cell_Therapy.asp
143. Stem cell therapy for multiple sclerosis - PMC - PubMed Central, accessed March 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6759045/
144. Research on Stem Cells and MS - National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/understanding-ms/ms-research/research-news-progress/stem-cells
145. Stem cell therapy for MS, accessed March 28, 2025, https://www.msif.org/research/challenges-of-ms-research/stem-cell-therapy-for-ms/
146. Center for Multiple Sclerosis and Autoimmune Neurology - Stem cell therapy - Mayo Clinic, accessed March 28, 2025, https://www.mayo.edu/research/centers-programs/center-multiple-sclerosis-autoimmune-neurology/research-programs/stem-cell-therapy
147. Precision Medicine & Personalized DMTs | National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/understanding-ms/ms-research/pathways-to-cures/stop-ms-in-its-tracks/precision-medicine
148. Personalized Medicine and Biomarker Innovations in Multiple Sclerosis Treatment: Enrique Alvarez, MD, PhD - NeurologyLive, accessed March 28, 2025, https://www.neurologylive.com/view/personalized-medicine-biomarker-innovations-ms-treatment-enrique-alvarez
149. Personalized Treatment for Multiple Sclerosis: The Role of Precision Medicine | Neurology Letters, accessed March 28, 2025, https://www.neurologyletters.com/article_170305_c0c383b712e98955468c72522b65fa7c.pdf
150. Personalised medicine for multiple sclerosis care - PubMed, accessed March 28, 2025, https://pubmed.ncbi.nlm.nih.gov/27672137/
151. Review: Precision Medicine for Multiple Sclerosis - Brigham On a Mission, accessed March 28, 2025, https://www.brighamhealthonamission.org/2023/03/17/review-precision-medicine-for-multiple-sclerosis/
152. Neuroprotection - MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/research/explore-our-research/emerging-research-and-treatments/neuroprotection
153. Neuroprotection - MS Trust, accessed March 28, 2025, https://mstrust.org.uk/a-z/neuroprotection
154. Is TSPO a good target for neuroprotection? - MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/research/explore-our-research/search-our-research-projects/is-tspo-a-good-target-for-neuroprotection
155. Targeting the NLRX1 Pathway for Neuroprotection in Multiple Sclerosis: Marjan Gharagozloo, PhD - NeurologyLive, accessed March 28, 2025, https://www.neurologylive.com/view/targeting-nlrx1-pathway-neuroprotection-ms-marjan-gharagozloo
156. Targeting Aging to Promote Neuroprotection in MS - MS Canada, accessed March 28, 2025, https://mscanada.ca/ms-research/our-research-program/research-studies-we-fund/targeting-aging-to-promote
157. Diet, Exercise & Healthy Behaviors | National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/managing-ms/living-with-ms/diet-exercise-and-healthy-behaviors
158. Target Coping Strategies for Interventions Aimed at Maximizing Psychosocial Adjustment in People with Multiple Sclerosis - PubMed Central, accessed March 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5991507/
159. Ready for a nap, but the desk is in the way? - MS Australia, accessed March 28, 2025, https://www.msaustralia.org.au/news/ready-for-a-nap-but-the-desk-is-in-the-way/
160. Canadian Physical Activity Guidelines for Adults with Multiple Sclerosis, accessed March 28, 2025, https://csepguidelines.ca/guidelines/multiple-sclerosis/
161. Exercise training guidelines for multiple sclerosis, stroke, and Parkinson's disease: Rapid review and synthesis - PMC - PubMed Central, accessed March 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6586489/
162. The Promotion of Exercise for Multiple Sclerosis, accessed March 28, 2025, https://www.nsca.com/education/articles/ptq/the-promotion-of-exercise-for-multiple-sclerosis/
163. The Role of Physical Exercise in Managing Multiple Sclerosis Symptoms - Cleveland Clinic, accessed March 28, 2025, https://my.clevelandclinic.org/departments/neurological/depts/multiple-sclerosis/ms-approaches/exercise-in-ms
164. Special Diets and MS - Advice & Support, accessed March 28, 2025, https://www.mssociety.org.uk/living-with-ms/physical-and-mental-health/eating-and-drinking/special-diets-and-ms
165. Diet & Nutrition for Multiple Sclerosis | National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/managing-ms/living-with-ms/diet-exercise-and-healthy-behaviors/diet-nutrition
166. Multiple Sclerosis (MS) Diet: Foods to Limit, Eat, and More - Healthline, accessed March 28, 2025, https://www.healthline.com/nutrition/multiple-sclerosis-foods-to-avoid
167. Sleep and MS - MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/living-with-ms/physical-and-mental-health/sleep-and-ms
168. Sleep and MS - MS Trust, accessed March 28, 2025, https://mstrust.org.uk/information-support/wellbeing-ms/sleep
169. Dream On: Managing Sleep Disorders - National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/news-and-magazine/momentum-magazine/living-well/managing-sleep-disorders
170. www.mssociety.org.uk, accessed March 28, 2025, https://www.mssociety.org.uk/living-with-ms/physical-and-mental-health/mental-health/getting-help#:~:text=You%20might%20find%20counselling%20useful,be%20called%20'peer%20support'.
171. Physical and mental health | MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/living-with-ms/physical-and-mental-health
172. Getting help with emotional support | MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/living-with-ms/physical-and-mental-health/mental-health/getting-help
173. Finding Emotional Support Resources - National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/resources/get-support/find-doctors-and-resources/emotional-support-guide
174. Helpful Resources - Centers for Multiple Sclerosis, accessed March 28, 2025, https://centers4ms.org/links/
175. Listing: Multiple Sclerosis (MS) Resources - Shirley Ryan AbilityLab, accessed March 28, 2025, https://www.sralab.org/lifecenter/resources/listing-multiple-sclerosis-ms-resources
176. Multiple Sclerosis Association of America – Improving Lives Today! | MSAA, accessed March 28, 2025, https://mymsaa.org/
177. Resources - University of Kansas Medical Center, accessed March 28, 2025, https://www.kumc.edu/research/center-for-ms-care/research/resources.html
178. Support Groups - Multiple Sclerosis Foundation, accessed March 28, 2025, https://msfocus.org/Get-Help/Support-Groups.aspx
179. National Multiple Sclerosis Society - Wikipedia, accessed March 28, 2025, https://en.wikipedia.org/wiki/National_Multiple_Sclerosis_Society
180. National MS Society - NeurologyLive, accessed March 28, 2025, https://www.neurologylive.com/sap-partner/national-ms-society
181. National Multiple Sclerosis Society - National Health Council, accessed March 28, 2025, https://nationalhealthcouncil.org/member/national-multiple-sclerosis-society/
182. National Multiple Sclerosis Society - GuideStar Profile, accessed March 28, 2025, https://www.guidestar.org/profile/13-5661935
183. Multiple Sclerosis Association of America (MSAA) - America's Charities, accessed March 28, 2025, https://www.charities.org/charities/multiple-sclerosis-association-america-msaa/
184. Multiple Sclerosis Association of America - National Organization for Rare Disorders, accessed March 28, 2025, https://rarediseases.org/organizations/multiple-sclerosis-association-of-america/
185. Rating for Multiple Sclerosis Association of America - Charity Navigator, accessed March 28, 2025, https://www.charitynavigator.org/ein/221912812
186. Multiple Sclerosis Association of America - Tiltify, accessed March 28, 2025, https://tiltify.com/multiple-sclerosis-association-of-america
187. Multiple Sclerosis Society UK - National Organization for Rare Disorders, accessed March 28, 2025, https://rarediseases.org/organizations/multiple-sclerosis-society-uk/
188. Multiple Sclerosis Society of Great Britain - Wikipedia, accessed March 28, 2025, https://en.wikipedia.org/wiki/Multiple_Sclerosis_Society_of_Great_Britain
189. Useful links - University College London Hospitals NHS Foundation Trust, accessed March 28, 2025, https://www.uclh.nhs.uk/our-services/find-service/neurology-and-neurosurgery/multiple-sclerosis-ms/useful-links
190. MULTIPLE SCLEROSIS SOCIETY - 1139257 - Charity Commission, accessed March 28, 2025, https://register-of-charities.charitycommission.gov.uk/charity-details/?regid=1139257&subid=0
191. What is MS? | MS Society UK - YouTube, accessed March 28, 2025, https://www.youtube.com/watch?v=nw2K5vDA1Zk
192. MS International Federation (MSIF), accessed March 28, 2025, https://mstrust.org.uk/a-z/ms-international-federation-msif
193. MSIF | European Charcot Foundation, accessed March 28, 2025, https://www.charcot-ms.org/initiatives/msif
194. MS International Federation | Multiple Sclerosis Society of NZ, accessed March 28, 2025, https://msnz.org.nz/multiple-sclerosis-international-federation-msif/
195. Multiple Sclerosis International Federation - National Organization for Rare Disorders, accessed March 28, 2025, https://rarediseases.org/organizations/multiple-sclerosis-international-federation/
196. Multiple Sclerosis International Federation - Wikipedia, accessed March 28, 2025, https://en.wikipedia.org/wiki/Multiple_Sclerosis_International_Federation
197. In Your Area: MS Community Chapters - National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/resources/get-connected/in-your-area
198. Tucson MS Self Help Group - Multiple Sclerosis Foundation - Search, accessed March 28, 2025, https://msfocus.org/Get-Help/Support-Groups/Search?State=AZ
199. Join a Support Group or Program | National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/resources/get-support/find-support-groups-and-programs
200. Multiple sclerosis support groups and resources, accessed March 28, 2025, https://multiplesclerosisnewstoday.com/support-groups-and-resources/
201. What Causes MS? Is MS Hereditary or Genetic? | MS Society UK, accessed March 28, 2025, https://www.mssociety.org.uk/about-ms/what-is-ms/causes-of-ms
202. What Causes Multiple Sclerosis (MS)? - National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/understanding-ms/what-is-ms/what-causes-ms
203. Is MS genetic? | The Role of Genetics in Multiple Sclerosis - Dementech Neurosciences, accessed March 28, 2025, https://dementech.com/2023/04/21/is-ms-genetic/
204. Environmental factors related to multiple sclerosis progression - World Federation of Neurology, accessed March 28, 2025, https://wfneurology.org/activities/news-events/archived-news/2024-09-11-wfn-jns-editors-choice
205. Lifestyle and Environmental Factors in Multiple Sclerosis - PMC - PubMed Central, accessed March 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6444694/
206. Viruses and infectious agents | National MS Society, accessed March 28, 2025, https://www.nationalmssociety.org/understanding-ms/what-is-ms/what-causes-ms/viruses
207. Multiple sclerosis: MedlinePlus Genetics, accessed March 28, 2025, https://medlineplus.gov/genetics/condition/multiple-sclerosis/
208. Genetics and MS - MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/research/explore-our-research/emerging-research-and-treatments/genetics-and-ms
209. Causes of MS | MS Trust, accessed March 28, 2025, https://mstrust.org.uk/information-support/about-ms/causes-ms
210. Risk Factors Associated with Multiple Sclerosis: A Case-Control Study in Damascus, Syria, accessed March 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8189778/
211. Environmental factors in multiple sclerosis - Taylor & Francis Online, accessed March 28, 2025, https://www.tandfonline.com/doi/full/10.1586/14737175.2013.865866
212. Modifiable environmental factors in multiple sclerosis - SciELO, accessed March 28, 2025, https://www.scielo.br/j/anp/a/RxFDVLkkt544pDq7pPVdKxQ/?lang=en
213. Viruses and MS - MS Society, accessed March 28, 2025, https://www.mssociety.org.uk/research/explore-our-research/emerging-research-and-treatments/viruses-and-ms
214. Infections and multiple sclerosis - PMC - PubMed Central, accessed March 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7152154/
215. Vitamin D and MS: Is there any connection? - Mayo Clinic, accessed March 28, 2025, https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/expert-answers/vitamin-d-and-ms/faq-20058258
216. Vitamin D & MS - Emerging Research & Treatment, accessed March 28, 2025, https://www.mssociety.org.uk/research/explore-our-research/emerging-research-and-treatments/vitamin-d
217. Vitamin D | MS Trust, accessed March 28, 2025, https://mstrust.org.uk/a-z/vitamin-d
218. What we know about vitamin D and MS, accessed March 28, 2025, https://www.mssociety.org.uk/research/latest-research/research-blog/what-we-know-about-vitamin-d-and-ms
219. Vitamin D and Multiple Sclerosis: A Comprehensive Review - PMC - PubMed Central, accessed March 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5990512/
220. Addressing Smoking in Persons With Multiple Sclerosis: State of the Science and Need for a Targeted Intervention | Nicotine & Tobacco Research | Oxford Academic, accessed March 28, 2025, https://academic.oup.com/ntr/article/26/2/250/7251262